Ocular Therapeutix Inc. (NASDAQ:OCUL) went down by -8.74% from its latest closing price compared to the recent 1-year high of $24.30. The company’s stock price has collected -7.62% of loss in the last five trading sessions. Press Release reported on 07/23/21 that Thinking about buying stock in Acorda Therapeutics, Ocular Therapeutix, Ocugen, Aerpio Pharmaceuticals, or Anavex Life Sciences?
Is It Worth Investing in Ocular Therapeutix Inc. (NASDAQ :OCUL) Right Now?
Plus, the 36-month beta value for OCUL is at 2.10. Opinions of the stock are interesting as 5 analysts out of 7 who provided ratings for Ocular Therapeutix Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 2 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $25.33. OCUL currently public float of 75.94M and currently shorts hold a 7.65% ratio of that float. Today, the average trading volume of OCUL was 1.07M shares.
OCUL’s Market Performance
OCUL stocks went down by -7.62% for the week, with a monthly drop of -22.97% and a quarterly performance of -29.96%, while its annual performance rate touched 31.97%. The volatility ratio for the week stands at 6.76% while the volatility levels for the past 30 days are set at 5.27% for Ocular Therapeutix Inc.. The simple moving average for the period of the last 20 days is -14.16% for OCUL stocks with a simple moving average of -30.79% for the last 200 days.
Analysts’ Opinion of OCUL
Berenberg, on the other hand, stated in their research note that they expect to see OCUL reach a price target of $27. The rating they have provided for OCUL stocks is “Buy” according to the report published on December 17th, 2020.
Raymond James gave a rating of “Strong Buy” to OCUL, setting the target price at $25 in the report published on November 13th of the previous year.
OCUL Trading at -18.40% from the 50-Day Moving Average
After a stumble in the market that brought OCUL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -53.62% of loss for the given period.
Volatility was left at 5.27%, however, over the last 30 days, the volatility rate increased by 6.76%, as shares sank -20.01% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -24.72% lower at present.
During the last 5 trading sessions, OCUL fell by -7.62%, which changed the moving average for the period of 200-days by +4.16% in comparison to the 20-day moving average, which settled at $12.99. In addition, Ocular Therapeutix Inc. saw -45.56% in overturn over a single year, with a tendency to cut further losses.
Reports are indicating that there were more than several insider trading activities at OCUL starting from LINDSTROM RICHARD L MD, who sale 10,000 shares at the price of $14.30 back on May 20. After this action, LINDSTROM RICHARD L MD now owns 90,000 shares of Ocular Therapeutix Inc., valued at $143,000 using the latest closing price.
SUMMER ROAD LLC, the 10% Owner of Ocular Therapeutix Inc., purchase 437 shares at $10.48 during a trade that took place back on Oct 16, which means that SUMMER ROAD LLC is holding 5,618,861 shares at $4,580 based on the most recent closing price.
Stock Fundamentals for OCUL
Current profitability levels for the company are sitting at:
- -361.13 for the present operating margin
- +80.06 for the gross margin
The net margin for Ocular Therapeutix Inc. stands at -894.31. The total capital return value is set at -66.07, while invested capital returns managed to touch -173.44. Equity return is now at value -326.00, with -73.80 for asset returns.
Based on Ocular Therapeutix Inc. (OCUL), the company’s capital structure generated 76.80 points at debt to equity in total, while total debt to capital is 43.44. Total debt to assets is 22.32, with long-term debt to equity ratio resting at 64.12. Finally, the long-term debt to capital ratio is 36.27.
When we switch over and look at the enterprise to sales, we see a ratio of 62.52, with the company’s debt to enterprise value settled at 0.05. The receivables turnover for the company is 2.35 and the total asset turnover is 0.10. The liquidity ratio also appears to be rather interesting for investors as it stands at 9.23.